Results 221 to 230 of about 31,317 (345)

Progress of Immunotherapies in Parkinson's Disease

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Parkinson's disease (PD) is caused by an immune disorder triggered by α‐synuclein, leading to a persistent neuroinflammatory cycle that drives the disease from non‐motor symptoms to the motor stage. Second, it presents active and passive immunotherapy strategies targeting α‐synuclein and their potential in slowing down the disease progression.
Yong Peng, Xu‐hui Kang, Shun‐yu Yao, Xiuli Zhang, Sugimoto Kazuo, Jia Liu, Miao‐qiao Du, Lan‐xin Lin, Dai‐yi Jiang, Quan Chen, Hong Jin   +10 more
wiley   +1 more source

Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model. [PDF]

Front Pharmacol
Ranjbari M, Fakhri S, Abbaszadeh F, Kiani A, Mohammadi-Noori E, Echeverría J.   +5 more
europepmc   +1 more source

Depletion of Dietary n-30 Fatty Acid Decreases the Binding Sites of Muscarinic Cholinergic Receptor in the Hippocampus of Rats Aged 30 Days in an Antagonist-Binding Study

, 2010
文子 金澤, 厚子 南條, 健四郎 藤本   +2 more
openalex   +1 more source

Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome [PDF]

, 2018
Hirotoshi Iihara, Hironori Fujii, Chiaki Yoshimi, Ryo Kobayashi, Nobuhisa Matsuhashi, Takao Takahashi, Kazuhiro Yoshida, Akio Suzuki   +7 more
openalex   +1 more source

Tramiprosate, the Active Agent of ALZ‐801, Modulates Amyloidogenic APP Processing and Tau Phosphorylation in a Cellular Model of Alzheimer's Disease

Drug Development Research, Volume 87, Issue 4, June 2026.
ABSTRACT ALZ‐801, a valine‐conjugated prodrug of tramiprosate, has recently been evaluated in a Phase III trial as a potential Alzheimer's disease (AD)‐modifying therapy. Tramiprosate reduces misfolding of amyloid beta (Aβ) monomers and inhibits oligomer formation. In the present study, we investigated tramiprosate's effects on amyloidogenic processing
Kevser Biberoglu, Ozden Tacal
wiley   +1 more source

Galanin Receptors in the Central Nervous System: Exploring Ligand Interactions, Signal Transduction, and Potential Clinical Implications. [PDF]

Molecules
Owczarek A, Blecharz-Klin K.
europepmc   +1 more source

Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation [PDF]

, 2019
Huan Yang, Hui Liu, Qiong Zeng, Gavin H. Imperato, Meghan E. Addorisio, Jianhua Li, Mingzhu He, Kai Cheng, Yousef Al‐Abed, Helena Erlandsson Harris, Sangeeta S. Chavan, Ulf Andersson, Kevin J. Tracey   +12 more
openalex   +1 more source

Bibliometric Analysis of Cubebenes and Related Sesquiterpenes: Natural Occurrence, Biosynthesis, Pharmacological Activities, and In‐Silico‐Based Future Therapeutic Potential

eFood, Volume 7, Issue 3, June 2026.
Cubebene‐related sesquiterpenes, found across diverse biological sources, exhibit promising pharmacological activities, including anti‐inflammatory, neuroprotective, and anticancer effects. This review highlights their molecular diversity, ADME profiles, and predicted multitarget interactions, underscoring their therapeutic relevance and potential in ...
Khadija Boualam, Ahmet B. Ortaakarsu, Sohaib Khatib, Mohamed A. Farag, Mansour Sobeh   +4 more
wiley   +1 more source

Long-Acting Muscarinic Antagonists for the Treatment of Difficult-to-Treat and Severe Asthma: A Narrative Review Focusing on Inflammation from Bench to Bedside. [PDF]

J Inflamm Res
Calzetta L, Manzetti GM, Pistocchini E, Lauro RF, Gholamalishahi S, Cazzola M, Rogliani P.   +6 more
europepmc   +1 more source

Effects of Biperiden (Cholinergic Muscarinic m1/m4 Receptor Antagonist) on Craving Nicotine: A Proof-Of-Concept Clinical Study [PDF]

Giovanna Lira Rosa Ciutti, Andréia Gomes Bezerra, Shirley Takahashi, José R. Jardim, Rosângela Vicente, José Carlos Fernandes Galduróz, Paola Palombo   +6 more
openalex   +1 more source